Evidence map›Paper›PMID 25156930›Full record

Observational studyAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine2014

The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.

Andrew A Monte, Kennon J Heard, Jenny Campbell, D Hamamura, Richard M Weinshilboum, Vasilis Vasiliou

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Trial
  3. A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Trial
  4. CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.Clinical pharmacology and therapeutics · 2018
    Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Expert opinion on drug metabolism & toxicology · 2022
    Review
  11. Article
  12. Pharmacogenetics: A Precision Medicine Approach to Combatting the Opioid Epidemic.Journal of the American College of Clinical Pharmacy : JACCP · 2022
    Article
  13. Review
  14. Article
  15. Review
  16. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Andrew A MonteDepartment of Emergency Medicine, University of Colorado, Aurora, CO; Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA; Rocky Mountain Poison & Drug Center, Denver, CO.
Kennon J Heard
Jenny Campbell
D Hamamura
Richard M Weinshilboum
Vasilis Vasiliou
University of Colorado Denver · USMayo Clinic in Arizona · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Montana · USWashington Poison Center · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI, WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
TRAINING GRANT IN CLINICAL PHARMACOLOGYT32GM008685 · NIGMS · MAYO CLINIC ROCHESTER · PI Liewei Wang · 1998 to 2026
$8.2M
INHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9M
Mouse Models for Alcohol Metabolism and Tissue InjuryR24AA022057 · NIAAA · YALE UNIVERSITY · PI VASILIOU, VASILIS · 2013 to 2022
$4.5M
Role and Molecular Mechanisms of Corneal Aldehyde DehydrogenaseR01EY011490 · NEI · YALE UNIVERSITY · PI VASILIOU, VASILIS · 2004 to 2013
$4.0M
Novel Role of Corneal Crystallins as Modulators of Cell Growth and TransparencyR01EY017963 · NEI · YALE UNIVERSITY · PI VASILIOU, VASILIS · 2007 to 2019
$3.7M
Pharmacogenomics of Breast Cancer Adjuvant ChemotherapyU01HG005137 · NHGRI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2009 to 2011
$2.1M
Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemiaR01CA132780 · NCI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2008 to 2013
$1.6M
The role of GSH in cornea and lens developmentR21EY021688 · NEI · YALE UNIVERSITY · PI VASILIOU, VASILIS · 2012 to 2013
$413k
Role of Mitochondrial Aldehyde Dehydrogenases in Ethanol Metabolism and ToxicityR21AA017754 · NIAAA · UNIVERSITY OF COLORADO DENVER · PI VASILIOU, VASILIS · 2009 to 2010
$411k
MOLECULAR MECHANISMS AND CORNEAL ALDEHYDE DEHYDROGENASER29EY011490 · NEI · UNIVERSITY OF COLORADO DENVER · PI VASILIOU, VASILIS · 1998 to 2002
$308k
NCATS NIH HHS UL1 TR001082NCI NIH HHS R01 CA132780NEI NIH HHS R01 EY011490NEI NIH HHS R01 EY017963NEI NIH HHS R21 EY021688NEI NIH HHS R29 EY011490NHGRI NIH HHS U01 HG005137NIAAA NIH HHS R13 AA021659NIAAA NIH HHS R21 AA017754NIAAA NIH HHS R24 AA022057NIGMS NIH HHS R01 GM028157NIGMS NIH HHS T32 GM008685NIGMS NIH HHS U19 GM061388
6 · The paper itself

Abstract

objectivesThe hepatic cytochrome 2D6 (CYP2D6) is a saturable enzyme responsible for metabolism of approximately 25% of known pharmaceuticals. CYP interactions can alter the efficacy of prescribed medications. Hydrocodone is largely dependent on CYP2D6 metabolism for analgesia, ondansetron is inactivated by CYP2D6, and oxycodone analgesia is largely independent of CYP2D6. The objective was to determine if CYP2D6 medication coingestion decreases the effectiveness of hydrocodone.

methodsThis was a prospective observational study conducted in an academic U.S. emergency department (ED). Subjects were included if they had self-reported pain or nausea and were excluded if they were unable to speak English, were less than 18 years of age, had liver or renal failure, or carried diagnoses of chronic pain or cyclic vomiting. Detailed drug ingestion histories for the preceding 48 hours prior to the ED visit were obtained. The patient's pain and nausea were quantified using a 100-mm visual analog scale (VAS) at baseline prior to drug administration and following doses of hydrocodone, oxycodone, or ondansetron. We used a mixed model with random subject effect to determine the interaction between CYP2D6 drug ingestion and study drug effectiveness. Odds ratios (ORs) were calculated to compare clinically significant VAS changes between CYP2D6 users and nonusers.

resultsA total of 250 (49.8%) of the 502 subjects enrolled had taken at least one CYP2D6 substrate, inhibitor, or inducing pharmaceutical, supplement, or illicit drug in the 48 hours prior to ED presentation. CYP2D6 drug users were one-third as likely to respond to hydrocodone (OR = 0.33, 95% confidence interval [CI] = 0.1 to 0.8) and more than three times as likely as nonusers to respond to ondansetron (OR = 3.4, 95% CI = 1.3 to 9.1). There was no significant difference in oxycodone effectiveness between CYP2D6 users and nonusers (OR = 0.53, 95% CI = 0.3 to 1.1).

conclusionsCYP2D6 drug-drug interactions appear to change effectiveness of commonly prescribed drugs in the ED. Drug-drug interaction should be considered prior to prescribing CYP2D6 drugs.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersCytochrome P-450 CYP2D6Drug InteractionsEmergency Service, HospitalFemaleHumansHydrocodoneMaleMiddle AgedNauseaOdds RatioOndansetronBiomarkersCytochrome P-450 CYP2D6HydrocodoneOndansetronOxycodone

Identifiers

PMID25156930
PMCPMC4150819
OpenAlexW2002028786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.